Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with Type 2 diabetes mellitus

Introduction Nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) is associated severe clinical outcomes. MicroRNA (miR)-210 has been reported to be related T2DM and lipid metabolism. This study aimed determine whether miR-210 can predict the effects of glimepiride linagliptin on NAFLD T2DM. Material methods A total 86 patients were randomly categorized into two groups treated either (5 mg/daily) or (2 for 6 months. Furthermore, real-time quantitative polymerase chain reaction was used evaluate expression level in patients’ serum. Results Compared glimepiride, able significantly reduce fasting blood glucose (P = 0.039). Moreover, positively correlated (r 0.272, P 0.011) h post-breakfast 0.245, 0.023). The insulin negatively −0.224, 0.038). Also, alanine transaminase (ALT) 0.438, < 0.001) ALT/aspartate aminotransferase ratio 0.382, expression. Conclusions In summary, not different from improving hepatic renal functions reducing level. linked levels function, which indicates its role as a prognostic biomarker treatment using glimepiride.